BioVie Inc.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of BioVie Inc. (NASDAQ: BIVI) between August 5, 2021 and November 29, 2023, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 19, 2024.

If you purchased BioVie Inc. securities during the Class Period and would like to join the action, please click “Join This Class Action.”

Class Period:August 5, 2021 through November 29, 2023


21 Days
If you purchased BioVie securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of the case:

According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:

  • the ongoing COVID-19 pandemic caused “limited access” to clinical trial sites, significantly affecting BioVie’s ability to conduct proper oversight of the clinical trial;
  • due to the “limited access” to the clinical trial sites, the trial was at higher risk of having “significant deviation from protocol and Good Clinical Practice (GCP) violations” and “anomalous data;”
  • BioVie was experiencing issues with the contact research organizations it had retained, creating greater risk of the trial being in non-compliance with GCPs;
  • BioVie had identified “higher than expected levels of deviations” in the data;
  • due to a “highly unusual level of suspected improprieties” there was a heightened risk a majority of the clinical trial subjects would be excluded;
  • as a result of the exclusions, there was a heightened material risk that the clinical trial would “not achieve statistical significance;” and
  • as a result of the foregoing, statements about BioVie’s business, operations, prospects, and/or compliance with GCP were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Follow us on:
Company Name: BioVie Inc.
Stock Symbol: BIVI
Class Period: August 5, 2021 through November 29, 2023
Court: United States District Court District of Nevada

Why Rosen Law

The Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, our firm recovered $438 million for investors.

Investors should carefully identify and select experienced counsel with a track record of success leading securities class actions. Often other firms issue press releases about class actions yet do not have comparable experience or resources.

Institutional Shareholders Services ranked the Rosen Law Firm # 1 for the number of securities class action recoveries in 2017.

The Rosen Law Firm represents investors throughout the globe. Our mission is to prosecute securities fraud class actions and protect shareholders’ rights.

Scroll to Top